Reports

Ideas That Generate Results

Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022

Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Jan, 2020| No. of Pages : 230

Share |
 
Please make your selection :
Electronic Access - Single User License
US$ 3000.00
CD-ROM Mail Delivery
US$ 3500.00
Hard Copy Mail Delivery
US$ 3500.00
Electronic Access - Multi-User License
US$ 6000.00

1. Analyst View

2. Research Methodology

3. Immuno-Oncology: Overview

4. Market Dynamics
    4.1 Drivers
          4.1.1 Increasing Cancer Incidences
          4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth
          4.1.3 Growing Geriatric Population
          4.1.4 High Healthcare Spending in Developed Economies
          4.1.5 Strong Pipeline
          4.1.6 Increasing Efficacy in a Wide Variety of Indications
          4.1.7 Burgeoning Approval and Uptake of Immuno-Oncology Products
    4.2 Challenges
          4.2.1 Patent Expiry of Top-Selling Drugs
          4.2.2 Increasing Number of Side-Effects Post Immunotherapy Treatment
          4.2.3 Sky-High Development Costs of Cancer Immunotherapies
          4.2.4 High Cost of Treatment
          4.2.5 Lack of Awarenes
    4.3 Opportunities
          4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunity
          4.3.2 Combination Therapies Could Lead to Substantial Increase in Survival
          4.3.3 CAR-T Therapies: The Future of Cancer Care
          4.3.4 Small Companies Offering Huge Opportunites for Next Generation Immunotherapies

5. Global Immuno-Oncology Market Outlook 2022

6. Global Immuno-Oncology Market, by Product Class
    6.1 Monoclonal Antibodies (mAbs)
          6.1.1 Naked Monoclonal Antibodies
                   6.1.1.1 Rituxan (Rituximab)
                   6.1.1.2 Avastin (Bevacizumab)
                   6.1.1.3 Herceptin (Trastuzumab)
          6.1.2 Conjugated Monoclonal Antibodies
                   6.1.2.1 ADCETRIS (Brentuximab vedotin)
                   6.1.2.2 Kadcyla (Ado-trastuzumab emtansine/TDM-1)
          6.1.3 Bispecific Monoclonal Antibodies
                   6.1.3.1 Blincyto (Blinatumomab)
          6.1.4 Others
    6.2 Therapeutic Vaccines
          6.2.1 Provenge
    6.3 Immune Checkpoint Inhibitors
          6.3.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)
                   6.3.1.1 Yervoy (Ipilimumab)
          6.3.2 PD-1 and PD-L1 Inhibitors(Programmed Death-1 and Programmed Death-Ligand 1)
                   6.3.2.1 Opdivo (Nivolumab)
                   6.3.2.2 Keytruda (Pembrolizumab)
    6.4 Others

7. Global Immuno-Oncology Market, By Major Indications
    7.1 Head & Neck Cancer
    7.2 Lung Cancer
    7.3 Melanoma
    7.4 Lymphoma
    7.5 Leukemia
    7.6 Others

8. Global Immuno-Oncology Market, By Geography
    8.1 North America
    8.2 Europe
    8.3 Asia-Pacific

9. Trends & Developments
    9.1 Lucrative Investment Trends
    9.2 Emergence of Targeted and Combination Therapies
    9.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market
    9.4 Bristol-Myers Squibb and Merck & Co: Top Immuno-Oncology Dealmakers

10. Strategic Collaborations & Alliances in the Immuno-Oncology Industry

11. Pipeline Analysis of Immuno-Oncology

12. Competitive Landscape
      12.1 Share of Major Players

13. Key Players Analysis
      13.1 F. Hoffmann-La Roche AG
      13.2 Celgene Corporation
      13.3 Bristol-Myers Squibb
      13.4 Merck & Co., Inc.
      13.5 Novartis
      13.6 AstraZeneca Plc
      13.7 Pfizer Inc
      13.8 Eli Lilly and Company
      13.9 Johnson & Johnson
      13.10 Amgen Inc.

Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.